drugset / Trial / NCT02423954
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Determine Phase 2 dose of study drug
Timeline
- Start
- 2015-04
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg | Oral |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 175 mg/m2 | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Temsirolimus | Small molecule | 25 mg | — |